文献速递胃肠动力与功能性疾病

基于价值的定价可增加腹泻型肠易激综合征患者获得利福昔明治疗的机会

Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-03-01

本研究构建决策分析模型,评估利福昔明治疗腹泻型肠易激综合征(IBS-D)在完全不予覆盖、无限制覆盖和处方集限制覆盖三种医保覆盖水平下的成本效果,并用阈值分析确定各覆盖水平下的最大成本有效药品价格。结果显示当前药价下无限制或处方集限制覆盖每获得一个质量调整生命年(QALY)的增量成本分别为1,207,136美元和171,850美元,需大幅降价方具成本效果。

要点

  • 无限制覆盖和处方集限制覆盖较完全不予覆盖分别多获得0.03和0.05个QALY。
  • 当前药价下,无限制覆盖每QALY增量成本为1,207,136美元,处方集限制覆盖为171,850美元。
  • 处方集限制覆盖需降价12%至62%(每片18.46至26.34美元)才具成本效果。

核心结论

  • 使用决策分析模型显示,当前药价下腹泻型肠易激综合征患者使用利福昔明的医保覆盖超出普遍接受的成本效果阈值。
  • 采用基于价值的定价方法可为改善医保覆盖提供依据。

研究设计与样本

  • 构建决策分析模型,评估利福昔明治疗腹泻型肠易激综合征患者的生活质量、成本和成本效果。
  • 设定完全不予覆盖(保险公司不支付任何药费)、无限制覆盖(保险公司支付100%药费)和处方集限制覆盖(初始治疗失败后保险公司支付100%药费)三种覆盖水平。
  • 采用阈值分析,按每质量调整生命年(QALY)50,000至150,000美元的支付意愿阈值,确定各覆盖水平下的最大成本有效药品价格。
  • 分析从支付方角度进行,时间范围为1年。

主要发现

  • 无限制覆盖和处方集限制覆盖比完全不予覆盖更有效,分别多获得0.03和0.05个QALY。
  • 无限制覆盖和处方集限制覆盖比完全不予覆盖费用更高。
  • 当前药价下,与完全不予覆盖相比,无限制覆盖每获得一个QALY需额外花费1,207,136美元,处方集限制覆盖每获得一个QALY需额外花费171,850美元。
  • 处方集限制覆盖需降价12%至62%(每片18.46至26.34美元),无限制覆盖需降价84%至88%(每片3.53至4.71美元),利福昔明才具成本效果。
  • 敏感性分析中,利福昔明再治疗间隔、应答率和不良事件是重要因素。

关键数值与推荐

  • 支付意愿阈值为每QALY 50,000至150,000美元。
  • 处方集限制覆盖下最大成本有效价格需较当前价格降低12%至62%(每片18.46至26.34美元)。
  • 无限制覆盖下最大成本有效价格需较当前价格降低84%至88%(每片3.53至4.71美元)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Increasing drug prices lead to payer coverage restrictions, which limit access to therapy. We assessed the cost effectiveness of rifaximin in management of patients with irritable bowel syndrome with diarrhea (IBS-D) under common payer coverage restrictions and determined the maximum price at which rifaximin would be cost effective using contemporary cost-effectiveness thresholds. METHODS: A decision analytic model was constructed to evaluate quality of life, cost, and cost effectiveness of rifaximin for patients with IBS-D and complete noncoverage (insurer pays none of the drug cost), unrestricted access (insurer pays 100% of the drug cost), and formulary-restricted access (insurer pays 100% of the drug cost after for patients failed by initial therapy). The maximum cost-effective drug price was determined for each level of drug coverage using threshold analysis adjusted for willingness to pay thresholds from $50,000 to $150,000 per quality-adjusted life year (QALY). Analysis was performed from a payer perspective with a 1-year time horizon. RESULTS: Unrestricted and formulary-restricted access were more effective than complete non-coverage, resulting in additional 0.03 and 0.05 QALYs gained over noncoverage. However, unrestricted and formulary-restricted coverage were more expensive. At current drug prices, unrestricted or formulary-restricted coverage would cost an additional $1,207,136 or $171,850/QALY gained, compared to complete non-coverage. A 12% to 62% price reduction ($18.46 to $26.34/pill) for formulary-restricted access and 84% to 88% price reduction ($3.53 to $4.71/pill) for unrestricted access would be needed for rifaximin to be a cost-effective treatment strategy. Rifaximin retreatment intervals, response rates, and adverse events were important factors in sensitivity analysis. CONCLUSION: Using a decision analytic model, we show that payer coverage for rifaximin for patients with IBS-D exceeds generally accepted cost-effectiveness thresholds at current drug prices. Improved payer coverage could be justified using value-based pricing methods.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shah ED, Saini SD, Chey WD, et al. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy. Clin Gastroenterol Hepatol. 2019. PMID: 30831219. doi:10.1016/j.cgh.2019.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。